Liu Kun, Chen Hong-Lin, Gu Ming-Ming, You Qing-Sheng
a Department of Cardiothoracic Surgery , Affiliated Hospital of Nantong University , Jiangsu , China.
b Nantong University , Jiangsu , China.
J Chemother. 2016 Jun;28(3):225-9. doi: 10.1179/1973947815Y.0000000041. Epub 2016 May 31.
The aim of this study was to investigate the predictive value of Nin one binding (NOB1) expression for response to cisplatin-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC).
A total of 105 consecutive patients with advanced NSCLC were retrospectively investigated between January 2012 and June 2014. We used transbronchial biopsy to collect cancer tissue samples. Immunohistochemistry were used in the detection of NOB1 protein expression. We assessed the chemotherapy early response by response evaluation criteria in solid tumours (RECIST) Version 1.1 at the end of the second cycle of chemotherapy.
In the 105 transbronchial biopsy NSCLC specimens, 22 (21.0%) stained NOB1 - , 35 (33.3%) stained +, 31 (29.5%) stained ++ and 17 (16.2%) stained +++. The early response rate to chemotherapy was 59.0% in overall NSCLC. Early response to chemotherapy has no relationship with patients' age, gender, smoke status, performance status and chemotherapy regimens (P>0.05), but related with TMN stage, histopathological grade, as well as NOB1 expression (P < 0.05). In squamous cell carcinoma and non-squamous cell carcinoma, same results were found. Logistic regression analysis showed TMN stage, histopathological grade and NOB1 expression were independent prognosis factors for early response to cisplatin-based chemotherapy in patients with advanced NSCLC. After adjusted by TMN stage and histopathological grade, the OR for NOB1 expression was 1.429 (95% CI 1.115-1.743, P = 0.008) for early response to chemotherapy.
Our results suggest that enhanced expression of NOB1 related with poor early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.
本研究旨在探讨NIN1结合蛋白（NOB1）表达对晚期非小细胞肺癌（NSCLC）患者顺铂化疗疗效的预测价值。
回顾性分析2012年1月至2014年6月期间连续收治的105例晚期NSCLC患者。采用经支气管活检收集癌组织样本，免疫组化法检测NOB1蛋白表达。化疗第二周期结束时，依据实体瘤疗效评价标准（RECIST）1.1版评估化疗早期反应。
105例经支气管活检的NSCLC标本中，22例（21.0%）NOB1染色为 - ，35例（33.3%）为 + ，31例（29.5%）为 ++ ，17例（16.2%）为 +++ 。NSCLC患者总体化疗早期反应率为59.0%。化疗早期反应与患者年龄、性别、吸烟状况、体能状态及化疗方案无关（P>0.05），但与TMN分期、组织病理学分级及NOB1表达有关（P<0.05）。在鳞状细胞癌和非鳞状细胞癌中，结果相同。Logistic回归分析显示，TMN分期、组织病理学分级及NOB1表达是晚期NSCLC患者顺铂化疗早期反应的独立预后因素。经TMN分期和组织病理学分级校正后，NOB1表达对化疗早期反应的比值比为1.429（95%可信区间1.115 - 1.743，P = 0.008）。
我们的研究结果表明，晚期非小细胞肺癌患者中，NOB1表达增强与顺铂化疗早期反应不佳相关。
